Previous 10 | Next 10 |
Taiwan Liposome (NASDAQ: TLC ) +103% on planned trial of inhaled malaria drug for COVID-19. More news on: Taiwan Liposome Company, Ltd., Mesoblast Limited, Midatech Pharma plc, Stocks on the move, , Read more ...
NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the United States Food and Drug Administration (FDA) voted overwhelmingl...
The FDA's Oncologic Drugs Advisory Committee voted 8-2 backing approval of Mesoblast Limited's (NASDAQ: MESO ) Ryoncil (remestemcel-L) (ex-vivo culture-expanded adult human mesenchymal stromal cells suspension for intravenous infusion) for the treatment of steroid-refractory acute graft-ve...
Shares of Mesoblast (NASDAQ: MESO) fell as much as 40% today after investors pored over a briefing document for an upcoming advisory committee (AdCom) meeting scheduled to take place on Aug. 13. The meeting will allow independent scientists to weigh in on the marketing application for remest...
Gainers: Biofrontera (NASDAQ: BFRA ) +75% . More news on: Biofrontera AG, Pfenex Inc., Oxbridge Re Holdings Limited, Stocks on the move, , Read more ...
Almost two hours into the session, Mesoblast Limited ( MESO -38.9% ) is down on triple normal volume as investors digest the details in the FDA briefing document related to the company's marketing application for Ryoncil (remestemcel-L) (ex-vivo culture-expanded adult human mesenchymal s...
Relief Therapeutics Holdings AG ( RLFTF ) is a Swiss Company that trades on the U.S. OTC Exchange in addition to its Swiss Stock Exchange Listing (RLF). Only a week ago, Relief Therapeutics was trading under .10 per share. It was the rediscovery of the properties of their drug RLF-100, a propr...
Mesoblast Limited (NASDAQ: MESO ) is down 21% premarket on modestly higher volume in reaction to the release of briefing materials for Thursday's meeting of the FDA's Oncologic Drugs Advisory Committee where it will review and discuss the company's marketing application for R...
Fennec Pharmaceuticals (NASDAQ: FENC ) -31% on FDA rejection of Pedmark application. More news on: Fennec Pharmaceuticals Inc., Mesoblast Limited, Genesis Healthcare, Inc., Stocks on the move, , Read more ...
NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today provided an update on the scheduled meeting of the Oncologic Drugs Advisory Committee (ODAC) of the United States Food and Drug Administration (FDA) which will review data supporting the Companyȁ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...